Genetic basis of variation in tenofovir drug susceptibility in HIV-1

AIDS

Volumn 22, Issue 10, 2008, Pages 1113-1123

  Murray, Robert J ^a   Lewis, Fraser I ^a,c   Miller, Michael D ^b   Brown, Andrew J Leigh ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GILEAD SCIENCES   (United States)

^c SAC   (United Kingdom)

Author keywords

Antiretroviral therapy; Antiviral drug resistance; Classification trees; Decision trees; HIV 1; Machine learning; Nucleoside reverse transcriptase inhibitors; Reverse transcriptase; Tenofovir; Thymidine analog mutations

Indexed keywords

AMINO ACID; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ACCURACY; ARTICLE; CLASSIFICATION; DECISION TREE; DRUG RESPONSE; DRUG SENSITIVITY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RANDOM FOREST; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LD 50; PREDICTION AND FORECASTING;

ADENINE; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LETHAL DOSE 50; MODELS, BIOLOGICAL; PHENOTYPE; PHOSPHONIC ACIDS; PREDICTIVE VALUE OF TESTS; VARIATION (GENETICS);

EID: 50949105386     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830184a1     Document Type: Article

References (54)

1. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleosideresistant HIV-1 Infection: a randomized trial. Ann Intern Med 2003; 139:313-320.
2. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16:1227-1235.
3. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
4. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
5. Srinivas RV, Fridland A. Antiviral activities of 9-R-2- phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998; 42:1484-1487.
6. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001; 20:1025-1028.
7. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. cience 1998; 282:1669-1675.
8. Larder BA, Stammers DK. Closing in on HIV drug resistance. Struct Biol 1999; 6:103-106.
9. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908-15917.
10. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75:4832-4842.
11. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A 1992; 89:1934-1938.
12. Shafer RW, Winters MA, Jellinger RM, Merigan TC. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J Infect Dis 1996; 174:448-449.
13. Wainberg MA, White AJ. Current insights into reverse transcriptase inhibitor-associated resistance. Antivir Ther 2001; 6(Suppl 2): 11-19.
14. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-1090.
15. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy: CNA2001 Investigative Group. J Infect Dis 2000; 181:912-920.
16. Winters MA, Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs. Antimicrob Agents Chemother 2001; 45:2276-2279.
17. Wang K, Jenwitheesuk E, Samudrala R, MittlerJE. Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance. Antivir Ther 2004; 9:343-352.
18. Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 2006; 103:17355-17360.
19. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, et al. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis 2000; 182:59-67.
20. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99:8271-8276.
21. Leigh Brown AJ, Frost SDW, Good B, Daar ES, Simon V, Markowitz M, et al. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of Human Immunodeficiency Virus type 1 strains in primary infection. J Virol 2004; 78:2242-2246.
22. Wang D, Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 2003; 188:653-660.
23. Rabinowitz M, Myers L, Banjevic M, Chan A, Sweetkind-Singer J, Haberer J, et al. Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization. Bioinformatics 2006; 22:541-549.
24. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003; 47:3478-3484.
25. Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2000; 28:346-348.
26. Kosakovsky Pond SL, Frost SDW, Muse SV. HyPhy: hypothesis testing using phylogenies. Bioinformatics 2005; 21:676-679.
27. Ross L, Boulme R, Fisher R, Hernandez J, Florance A, et al. A direct comparison of drug susceptibility to HIV-1 type 1 from antiretroviral experienced subjects as assessed by the Antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res Hum Retroviruses 2005; 21:933-939.
28. Zhang J, Rhee SY, Taylor J, Shafer RW. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 2005; 38:439-444.
29. Petropoulos CJ, Parkin NT, Limoli Y, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Ag Chemo 2000; 44:920-928.
30. DiRienzo AG, DeGruttola V, Larder B, Hertogs K. Nonparametric methods to predict HIV drug susceptibility phenotype from genotype. Stats In Med 2003; 22:2785-2798.
31. Box GEP, Cox DR. An Analysis of Transformations. J Roy Stat Soc B 1964; 26:211-252.
32. Royston JP. An extension of shapiro and Wilk-W test for normality to large samples. J Roy Stat Soc C 1982; 31:115-124.
33. Masquelier B, Tamalet C, Montes B, Descamps D, Peytavin G, Bocket L, et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 2004; 9:315-323.
34. Miller MD. K65R, TAMs and tenofovir. AIDS Rev 2004; 6:22-33.
35. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846.
36. Breiman L, Friedman JH, Olshen RA, Stone CJ.Classification and regression trees. Belmont, CA: Wadsworth International; 1984.
37. Quinlan JR. C4.5: Programs for machine learning. San Francisco: Morgan Kaufman; 1993.
38. Breiman L. Random forests. Machine Learning 2001; 45:5-32.
39. Varma S, Simon R. Bias in error estimation when using crossvalidation for model selection. BMC Bioinformatics 2006; 7:91.
40. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating characteristic curves in biomedical informatics. J Biomedical Informatics 2005; 38:404-415.
41. Agence Nationale de Recherches sur le SIDA, Groupe AC11 (ANRS-AC11), Paris, France. ANRS-AC11 genotypic interpretation guidelines - version 16. Electronic citation, 2007. Available at: http://www.hivfrenchresistance.org/. [Accessed December 2007].
42. Vercauteren J, Van Laethem K, Deforche K, et al. REGA genotypic resistance interpretation system - version 6.4 Electronic citation, 2004. Available at: http://www.rega.kuleuven.be/cev/. [Accessed December 2007].
43. Shafer RW, Rhee SY, Zioni R, et al. HIV drug resistance database, Stanford University - version 4.2 Electronic citation, 2007. Available at: http://hivdb.stanford.edu/pages/algs/HIVdb.html. [Accessed: June 2007].
44. Beerenwinkel N, Schmidt B, Walter H, et al. geno2pheno genotypic resistance interpretation system. Electronic citation, 2007. Available at: http://www.geno2pheno.org/. [Accessed June 2007].
45. Beerenwinkel N, Sing T, Lengauer T, et al. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005; 21:3943-3950.
46. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.
47. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
48. Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004; 48:3122-3126.
49. Mendoza CD, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 2007; 23:879-885.
50. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179:92-100.
51. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 2007; 21:665-675.
52. Hertogs K, Bloor S, De V, V, van Den Eynde C, Dehertogh P, van Cauwenberge A, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000; 44:568-573.
53. Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse- transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
54. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17:791-799.